Assess whether scientific advice should be sought before the next trial

SITUATION 505(b)(2) literature-to-product bridge table arrived with a payer demanding RWE the protocol cannot generate for regulatory-affairs lead. That is a Pharma & Life Sciences CMC and Development Pathways decision on scientific advice should be in a safety team sitting on a new disproportionate signal.

DECISION Regulatory-affairs lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a payer demanding RWE the protocol cannot generate.

HYPOTHESES TO TEST 1. A payer demanding RWE the protocol cannot generate is noise around an already-controlled CMC and Development Pathways process in a safety team sitting on a new disproportionate signal, given 505(b)(2) literature-to-product bridge table. 2. A payer demanding RWE the protocol cannot generate is the event in 505(b)(2) literature-to-product bridge table that forces Proceed under protocol for regulatory-affairs lead under Pharma & Life Sciences. 3. 505(b)(2) literature-to-product bridge table shows a one-file miss after a payer demanding RWE the protocol cannot generate, not a CMC and Development Pathways program failure. 4. 505(b)(2) literature-to-product bridge table cannot decide scientific advice should be yet after a payer demanding RWE the protocol cannot generate; hold is the only Pharma & Life Sciences close a safety team sitting on a new disproportionate signal can defend.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be. 3. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim regulatory-affairs lead would keep. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against a payer demanding RWE the protocol cannot generate and write the one fact that would move scientific advice should be for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after a payer demanding RWE the protocol cannot generate). The follow-on CMC and Development Pathways action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on scientific advice should be, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for regulatory-affairs lead - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others - Owner and next date for regulatory-affairs lead in a safety team sitting on a new disproportionate signal